Piramal Pharma expects to maintain mid-teen revenue growth in FY27 and achieve a significant improvement in profitability, supported by strong demand across its businesses and improved operational efficiency. Chairperson Nandini Piramal said the company will continue to focus on organic expansion rather than acquisitions as it builds long-term growth.
The company reported a strong performance in the April-June quarter, with consolidated revenue rising 17 per cent year-on-year to Rs 2,270 crore. Earnings before interest, taxes, depreciation and amortisation (EBITDA) increased 72 per cent to Rs 285 crore, while the EBITDA margin expanded to 12.5 per cent from 8.5 per cent a year earlier, driven by higher capacity utilisation and better execution.
Piramal Pharma said all three of its business segments — Contract Development and Manufacturing Organisation (CDMO), Complex Hospital Generics (CHG) and Consumer Healthcare — recorded mid- to high-teen growth during the quarter. The company expects EBITDA to grow faster than revenue, supported by operating leverage and improved scale.
The CDMO business, which contributes more than half of the company’s revenue, grew 19 per cent to Rs 1,187 crore during the quarter. Piramal attributed the performance to improved biopharma funding, strong demand from customers in India and overseas markets, and enhanced business development efforts.
The company believes a favourable demand environment, particularly in the US biopharma sector, will continue to support growth and strengthen its financial performance in the coming year.
